Articles

Lilly CEO got 10-percent pay boost last year

Lilly CEO John Lechleiter was paid $11.2 million in salary, bonus, stock and perks last year, according to Lilly’s proxy statement filed Monday morning. That represented a 10-percent increase over his take in 2012.

Read More

Endocyte stock doubles after key approval in Europe

The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.

Read More

WellPoint raises 2014 earnings forecast

WellPoint is already raising a 2014 earnings forecast it laid out earlier this year, but the nation’s second-largest health insurer’s projections are still below analyst expectations.

Read More

Bold developer stirs up nursing-home business

Zeke Turner, the 36-year-old CEO of Mainstreet Property Group LLC—who frequently sports a boyish grin and a bold-colored dress shirt, but rarely dons a tie—said he’s “just getting started” in transforming the staid nursing home industry.

Read More

Top 10 most profitable hospitals around Indianapolis

Based on 2012 data, 23 of 30 hospitals in central Indiana are generating profits from their operations of 10 percent or more. The Indiana Orthopaedic Hospital and St. Vincent's Carmel campus are on top. After that, there are a few surprises.

Read More

Discovery may be key to Alzheimer’s treatment

Scientists have discovered that a gene-regulating protein that protects the developing brain of a fetus resurfaces in old age and may stave off dementia, a finding that could open a new path in Alzheimer’s research.

Read More

Hurdles remain for Roche Diagnostics on HPV test

Roche could enjoy a huge increase in sales of its HPV tests if all doctors and women followed a recommendation issued last week by an advisory committee at the FDA. But wrinkles in the U.S. health care system still present several big obstacles.

Read More

Republicans needed to make Obamacare work

Obama’s latest delay of Obamacare insurance rules could sabotage the law’s exchanges. The president must be counting on Republican critics, like Indiana Insurance Commissioner Stephen Robertson, to stop him.

Read More

Timing looks right for Biomet IPO

After private equity firms paid $11.4 billion for Biomet Inc. just months before the onset of a prolonged downturn, they are now trying to take the company public when U.S. consumer sentiment is on the upswing.

Read More

Health insurance brokers must change to survive

Employees, rather than employers, will soon choose their own health insurers—either through the Obamacare exchanges or through private exchanges. Does that mean health insurance brokers, the people who match up employers with insurers, will no longer be needed?

Read More